In the field of regenerative medicine products, we are giving priority to projects using mesenchymal stem cells, and are currently in the process of developing therapies using stem cells from human exfoliated deciduous teeth (SHED), high purity mesenchymal stem cells (RECs: Rapidly Expanding Cells), and umbilical cord-derived mesenchymal stromal cells (HLC-001).
SHED
SHED (stem cells from human exfoliated deciduous teeth) are stem cells taken from the pulp cavity inside the tooth and are a type of mesenchymal stem cell. It is expected to be utilized in the future source of cells for regenerative medicine products that can be stably supplied domestically. We are working on the commercialization of regenerative medicine products with S-Quatre Corporation, which is an expert in human dental pulp-derived stem cells.
RECs
High purity mesenchymal stem cells or RECs (Rapidly Expanding Cells) are isolated from bone marrow aspirate and purified by a unique method established by PuREC Co., Ltd. These cells have superior proliferative, differentiation, and migratory capacities compared to mesenchymal stem cells isolated by conventional methods.
HLC-001
HLC-001 is a cell therapy product using mesenchymal stromal cells obtained from the umbilical cord, which is the tissue connecting the placenta and the fetus. We are working with Human Life CORD Japan Inc. which is using HLC-001 in research and development targeting multiple intractable disease on the commercialization of HLC-001.